The U.S. FDA granted Orphan Drug Designation for OBI Pharma Inc.’s first-in-class antibody drug conjugate (ADC) OBI-999 for the treatment of pancreatic cancer.

Clovis Oncology Inc. entered into a global licensing and collaboration agreement with 3B Pharmaceuticals GmbH, a private German biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for oncology indications with a high unmet medical need.